Global Non-Invasive Prenatal Testing (NIPT) Market 2018-2028 by Test, Method, Platform, Application & Region

DUBLIN, Oct 30, 2018 /PRNewswire/ --

The "Global Non-Invasive Prenatal Testing (NIPT) Market: Focus on Tests, Methods, Platforms, Applications, 26 Countries' Analysis, Patent Landscape, and Competitive Landscape - Analysis and Forecast, 2018-2028" report has been added to ResearchAndMarkets.com's offering.

Global Non-Invasive Prenatal Testing (NIPT) Market to Deliver $5.67 Billion with 7,591,792 Units by 2028

Non-invasive prenatal testing (NIPT) is a sophisticated method used for the screening of chromosomal abnormalities developing in the fetus. It is a novel genetic screening method based on the analysis of cell-free fetal deoxyribose nucleic acid (cff-DNA) in the maternal plasma. The genetic screening is performed between 10-22 weeks of time frame, with small amount of blood sample and requires a minimum of 10 weeks of pregnancy for apt results. It is commercializing at a rapid pace due to emerging technologies for non-invasive analysis of the fetal genome, thus reducing the cost-effectiveness of NIPT. The exponential growth of the NIPT market is supported by various factors, such as reimbursement policies, insurance coverage, high incidence rate of Down syndrome, no risk of miscarriage with NIPT, and shifting trend toward child birth at an advanced maternal age (35 years or above).

Since the past few years (2011-2017), prenatal genetic testing has come up with new innovative and non-invasive technologies and testing options. However, it has been a challenge for women's healthcare providers to keep up with the swarm of publications and provide patients with the most accurate information regarding prenatal testing. Since a decade, researchers, physicians, and even pregnant women have been observing the benefits of a non-invasive tests that could potentially replace amniocentesis and chorionic villus sampling (CVS), and minimize the false positive results generated by them. Hence, with the advent of NIPT, there has been a reduction in the number of women undergoing highly invasive procedures.

The purpose of the study is to gain a holistic view of the NIPT market in terms of various factors influencing it such as recent trends and technological advancements of the market. The scope of this report is centered upon conducting a detailed study of the tests associated with the global NIPT market across different regions. The global NIPT market is segmented into five different parts namely by tets, by method, by platform, by application, and by region. The global market value and volume was estimated using these three different approaches and was validated with one another. The global NIPT market is expected to reach $5.67 billion with 7,591,792 units by 2028.

With the increasing demand for technological advancements in NIPT across various segments of the NIPT, the NIPT market is expected to witness rapid growth in the future. Further, the increasing insurance coverage and reimburesement policies in the developed markets such as the U.S., Japan, Germany, and the U.K. is the key driver for the growth of the NIPT market. Moreover, the Panorama test dominated the global NIPT market in 2017 among different commercialized tests. However, the IONA test is anticipated to witness the highest CAGR during the forecast period. The trisomy detection application of NIPT witnessed the highest industry demand. Further, the NGS platform for NIPT is also expected to witness impressive CAGR during the forecast period.

On the basis of regions, the global NIPT market is segmented into North America, Europe, Asia-Pacific, and Rest-of-the-World (RoW). North America is the leading contributor to the global NIPT market and contributed 51.55% and 52.31% in terms of revenue and volume respectively to the global market in 2017. However, Asia-Pacific is expected to grow at a CAGR of 18.01% and 19.13% in terms of revenue and volume respectively during the forecast period.

Key Topics Covered:

Executive Summary

1 Market Overview
1.1 Introduction
1.2 NIPT Approach
1.3 Different Methods of NIPT
1.4 Benefits and Risks Associated with NIPT
1.5 Technological Advancements
1.6 World Economic Outlook of Prenatal Testing Market, 2017
1.7 Global NIPT Market Scenario
1.8 Assumptions and Limitations for Market Size Calculations

2 Market Dynamics
2.1 Overview
2.2 Impact Analysis
2.3 Market Drivers
2.4 Market Restraints
2.5 Market Opportunities

3 Competitive Landscape
3.1 Introduction
3.2 Key Developments and Strategies
3.2.1 Product Launches and Enhancements
3.2.2 Joint Ventures, Partnerships, and Collaborations
3.2.3 Mergers and Acquisitions
3.2.4 Business Expansions, Awards, Recognitions, Certifications, and Others
3.3 Market Share Analysis
3.4 Growth Share Matrix (by Test), 2017
3.5 Growth Share Matrix (by Region), 2017
3.6 Key Stakeholders of NIPT Market
3.7 Industry Attractiveness
3.7.1 Bargaining Power of Suppliers
3.7.2 Bargaining Power of Buyers
3.7.3 Threat of New Entrants
3.7.4 Threat of Substitute Products
3.7.5 Intensity of Competitive Rivalry

4 Industry Insights
4.1 Introduction
4.2 Patent Analysis
4.3 Clinical Laboratory Improvement Amendments (CLIA) Program
4.4 List of Regulatory Bodies

5 Global Non-Invasive Prenatal Testing (NIPT) Market (by Test)
5.1 Overview
5.2 Verifi
5.3 MaterniT21 PLUS and MaterniT GENOME
5.4 PrenaTest, GeneSafe, and PrenatalSAFE
5.5 Panorama
5.6 QNatal Advanced
5.7 Harmony
5.8 IONA
5.9 NIFTY
5.10 Bambni
5.11 Others

6 Global Non-Invasive Prenatal Testing (NIPT) Market (by Method)
6.1 Overview
6.2 cf-DNA
6.3 FCMB

7 Global Non-Invasive Prenatal Testing (NIPT) Market (by Platform)
7.1 Overview
7.2 NGS
7.3 MPSS
7.4 Others

8 Global Non-Invasive Prenatal Testing (NIPT) Market (by Application)
8.1 Overview
8.2 Trisomy Detection
8.3 Microdeletion Detection
8.4 Others

9 Global Non-Invasive Prenatal Testing (NIPT) Market (by Region)

10 Company Profiles

• Agilent Technologies, Inc.
• Annoroad Gene Technology
• BGI Diagnosis
• Berry Genomics Co., Ltd.
• Centogene AG
• Counsyl, Inc.
• EUROFINS Genoma Group (Subsidiary of Eurofins Scientific)
• Eurofins Scientific
• F. Hoffmann-La Roche AG
• Illumina, Inc.
• Laboratory Corporation of America Holdings
• LifeCodexx AG (Subsidiary of Eurofins Scientific)
• Myriad Genetics, Inc.
• NIPD Genetics
• Natera, Inc.
• Next Biosciences
• PerkinElmer, Inc.
• Premaitha Health Plc
• Quest Diagnostics Incorporated
• Sequenom, Inc. (Subsidiary of Laboratory Corporation of America Holdings)

For more information about this report visit https://www.researchandmarkets.com/research/m482qk/global?w=5

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Did you know that we also offer Custom Research? Visit our Custom Research page to learn more and schedule a meeting with our Custom Research Manager.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]   

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets

Related Links

http://www.researchandmarkets.com